We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Fate of novel painkiller mAbs hangs in balance.
- Authors
Garber, Ken
- Abstract
The article reports on the major setback suffered by a new class of pain medications after the U.S. Food and Drug Administration (FDA) placed a hold on many clinical trials for experimental therapies targeting nerve growth factor (NGF) in December 2010. It says that the fate of anti-NGF painkillers is yet to be decided after the move. The author adds that Pfizer is leading the quest for new painkillers with tanezumab, which is a humanized monoclonal antibody (mAb) that blocks NGF. The capacity of anti-NGF antibodies to control pain is also discussed.
- Subjects
UNITED States; PAIN medicine; UNITED States. Food &; Drug Administration; CLINICAL trials; NERVE growth factor; MEDICAL research
- Publication
Nature Biotechnology, 2011, Vol 29, Issue 3, p173
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0311-173